Quick Heal Technologies Limited has informed the Exchange regarding Outcome of Board Meeting held on May 06, 2025.
QUICKHEAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Quick Heal's Board approved audited consolidated and standalone results for FY25 (year ended March 31, 2025). FY25 revenue fell 4.2% YoY to ₹279.5 Cr, dragged by a weak consumer segment (₹185.7 Cr, -9.2% YoY), while enterprise revenue grew modestly to ₹121.2 Cr (+1.5%). The company slipped into negative territory on profitability with EBITDA of ₹(6.6) Cr versus ₹17.6 Cr last year, and PAT collapsed 79% to ₹5.0 Cr. Q4 FY25 was particularly weak, with revenue down ~19% YoY at ₹65.1 Cr and a loss of ₹(3.3) Cr. Operating cash flow turned negative at ₹(22.3) Cr versus ₹18.2 Cr inflow a year ago, largely due to a ₹38.8 Cr jump in trade receivables. Statutory auditors (MSKA & Associates) issued an unmodified opinion, and Ruchi Bhave was appointed as Secretarial Auditor for five years.
Weak set of numbers – top-line decline, negative EBITDA, sharply lower PAT and negative operating cash flow signal pressure on the business. The stock, already trading near its 52-week low (₹272.50 vs ₹825.90 high), may face further negativity in the near term, though the company highlighted a ₹24+ Cr order book and ₹12+ Cr deferred revenue as forward-looking positives.